Authors

Latest:

Dr Hitchins on Investigating Constitutional MLH1 Methylation in CRC and Endometrial Cancers

Megan Hitchins, PhD, discusses the rationale for conducting an analysis on the prevalence of high-risk constitutional MLH1 methylation in patients with early-onset colorectal cancer and endometrial cancer.

Onyee Chan, MD

Latest:

Clinical Perspectives: A 45-Year-Old Man With R/R CML

Panelists discuss a complex case of chronic myeloid leukemia (CML) progression in a younger patient, highlighting the critical importance of mutation testing, careful tyrosine kinase inhibitor (TKI) selection based on comorbidities, and adaptive treatment strategies to manage resistance and optimize outcomes.

Ariel Grajales-Cruz, MD

Latest:

Dr Grajales-Cruz on Real-World Teclistamab Data in BCMA-Pretreated Multiple Myeloma

Ariel Grajales-Cruz, MD, discusses the rationale for a real-world study of teclistamab in patients with myeloma who had received BCMA-directed therapy.

Moritz Fürstenau MD

Latest:

Dr Fürstenau on Safety Data From the GAIA/CLL13 Trial in Untreated CLL

Moritz Fürstenau, MD, discusses the safety of venetoclax plus obinutuzumab with/without ibrutinib in fit patients with chronic lymphocytic leukemia.

Fadi Haddad, MD

Latest:

Updates on the Treatment of Chronic Myeloid Leukemia Failing Frontline Therapy

Fadi Haddad, MD, discusses updates on the treatment of chronic myeloid leukemia failing frontline therapy.

Tashanna K. Myers, MD

Tashanna K. Myers, MD, is a professor of obstetrics and gynecology at the UMass Chan Medical School—Baystate

Latest:

Dr Myers on Mitigation Strategies for Ocular AEs in Platinum-Resistant Ovarian Cancer

Tashanna K. Myers, MD, discusses the importance of telling patients with ovarian cancer about the HRQOL outcomes associated with mirvetuximab soravtansine.

Natasha B Hunter, MD

Latest:

Dr. Hunter on the Role of 18F-FES-PET Imaging in Triple-Positive Breast Cancer

Natasha B Hunter, MD, discusses the utility of 18F-Fluoroestradiol PET imaging for patients with estrogen receptor–positive and HER2-positive breast cancer.

Brett L. Ecker, MD

Latest:

Dr Ecker on the Role of CAPETEM in the Treatment of Pancreatic NETs

Lindsey Roeker, MD

Latest:

Dr. Roeker on the Rationale for BTK/Venetoclax Combos in CLL

Lindsey Roeker, MD, discusses the rationale for combining venetoclax with BTK inhibitors for use in patients with chronic lymphocytic leukemia.

Bob T. Li, MD, PhD, MPH

Latest:

Dr Li on the Investigation of BDC-1001 in HER2-expressing Solid Tumors

Bob T. Li, MD, PhD, MPH, discusses the results of a phase 1/2 study of the first-in-class immune-stimulating antibody conjugate BDC-1001 in patients with advanced HER2-expressing solid tumors.

Nagi S. El-Saghir, MD, FACP, FASCO

Nagi S. El-Saghir, MD, FACP, FASCO is Professor of Clinical Medicine, Head of the Division of Hematology Oncology, Department of Internal Medicine and Director of the Breast Center of Excellence, Naef K Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.

Latest:

Dr El-Saghir on the Investigation of Ribociclib Plus ET in HR+, HER2– Advanced Breast Cancer

Nagi S. El-Saghir, MD, FACP, FASCO, discusses the inception of the phase 2 RIGHT Choice trial of ribociclib plus ET.

Joyce O’Shaughnessy, MD

Latest:

Clinical Perspectives on Biomarker Testing in mBC

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI

Latest:

Dr. McDermott on Preventing Recurrence of High-Risk Prostate Cancer

Ray McDermott, discusses preventing recurrence in patients with very high-risk prostate cancer.

Elisabet E. Manasanch, MD

Latest:

Clinical Trials in R/R Multiple Myeloma

Dr Joseph Mikhael and expert panel discuss key efficacy and safety outcomes of pivotal clinical trials evaluating treatment regimens in patients with R/R multiple myeloma.

Stephen Liu, MD, Georgetown University School of Medicine

Latest:

Updates in Immunotherapy for Advanced Thoracic Malignancies

Jeff Patton, MD

Laura Van Metre Baum, MD

Latest:

Normalizing Motherhood in Medicine

Hematology/oncology programs can make it easier and more rewarding for would-be mothers to participate in fellowship.

Elizabeth Shaughnessy, MD, PhD

Latest:

Women in Oncology: Self-Advocacy in a Busy Field

Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.

Alan P. Skarbnik, MD, Novant Health Cancer Institute

Latest:

Relapsed/Refractory CLL Treatment: Addressing Unmet Needs

Patrick Y. Wen, MD

Patrick Y. Wen, MD, is is the director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute; as well as a professor of neurology at Harvard Medical School

Latest:

Detailing the Exploration of Plixorafenib in CNS Malignancies

Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the novel BRAF inhibitor plixorafenib and its ongoing evaluation in central nervous system malignancies.